Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 5Terminated 2Unknown 1

Sponsor Class

NIH 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Melanoma 1Lymphopenia 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Interleukin-7 × Clear all
NCT03941769 2024-10-17

2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II

M.D. Anderson Cancer Center

Phase 1/2 Completed
1 enrolled 5 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT03513952 2024-07-26

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
47 enrolled 14 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT00091338 2015-04-30

Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

National Cancer Institute (NCI)

Phase 1 Completed
Dermatologic

Melanoma

NCT01368107 2015-02-09

Study Evaluating Impact of IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients

Centre Leon Berard

Phase 2 Completed
24 enrolled
Breast

Breast Neoplasms, Lymphopenia

NCT00062049 2012-03-08

Interleukin-7 in Treating Patients With Refractory Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
30 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡